ICD10 Disease Category |
Disease Name |
ICD10 Code |
Associated Disease Targets (Association Ref: TTD database) |
C00-D49: Neoplasms |
Castration-resistant prostate cancer |
C61 |
AR; |
I00-I99: Diseases of the circulatory system |
Cardiovascular disorder |
I00-I99 |
KDR; AR; |
I00-I99: Diseases of the circulatory system |
Cardiac arrhythmias |
I47-I49 |
ADORA1; |
I00-I99: Diseases of the circulatory system |
Cardiac disease |
I00-I99 |
ADORA1; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure |
Radionuclide imaging |
W88 |
ADORA2A; |
N00-N99: Diseases of the genitourinary system |
Infertility |
N97.0 |
ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders |
Insomnia |
F51.0, G47.0 |
CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Inflammation |
E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 |
ADORA3; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Female hypogonadism |
E23, E28 |
ESR1; |
C00-D49: Neoplasms |
Adrenocortical carcinoma |
C74.0 |
ESR1; |
C00-D49: Neoplasms |
Carcinoma |
D00-D09 |
ESR1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified |
Cachexia |
R64 |
AR; ESRRA; |
C00-D49: Neoplasms |
Cancer |
C00-C96 |
ESR1; PIM1; MET; CDK1; IGF1R; KDR; AR; FLT3; ADORA3; CDC25B; |
C00-D49: Neoplasms |
Hepatocellular carcinoma |
C22.0 |
MET; IGF1R; KDR; ADORA3; |
N00-N99: Diseases of the genitourinary system |
Renal failure |
N17, N18, N19 |
ADORA1; |
C00-D49: Neoplasms |
Renal cell carcinoma |
NA |
KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Testosterone deficiency |
E29.1 |
AR; |
A00-B99: Certain infectious and parasitic diseases |
Trematode infection |
B66.9 |
ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Type 2 diabetes |
E11 |
FFAR1; |
I00-I99: Diseases of the circulatory system |
Coronary disorder diagnosis |
I20-I25 |
ADORA2A; |
N00-N99: Diseases of the genitourinary system |
Irregularities |
N92.6 |
ESR1; |
C00-D49: Neoplasms |
Advanced renal cell carcinoma |
C64 |
KDR; |
C00-D49: Neoplasms |
Brain cancer |
C71, D33 |
ESR1; |
C00-D49: Neoplasms |
Breast cancer |
C50 |
ESR1; CDK1; IGF1R; KDR; AR; FLT3; |
C00-D49: Neoplasms |
Non-small-cell lung cancer |
NA |
KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Psoriasis |
L40 |
FLT3; |
C00-D49: Neoplasms |
Leukemia |
C90-C95 |
ESR1; FLT3; |
C00-D49: Neoplasms |
Liver cancer |
C22 |
IGF1R; KDR; |
C00-D49: Neoplasms |
Bladder cancer |
C67 |
AR; |
C00-D49: Neoplasms |
Biliary cancer |
C22, C24 |
KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Psoriatic disorder |
L40 |
IGF1R; |
N00-N99: Diseases of the genitourinary system |
Vagina disease |
N76.0 |
ESR1; |
K00-K95: Diseases of the digestive system |
Liver disease |
K70-K77 |
MET; |
C00-D49: Neoplasms |
Acute myeloid leukemia |
C92.0 |
AURKB; FLT3; |
C00-D49: Neoplasms |
Acute lymphoblastic leukemia |
C91.0 |
FLT3; |
C00-D49: Neoplasms |
CLL |
NA |
FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders |
Cognitive disorders |
F01-F07, F04, F05, R41.3 |
ADORA1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Muscle atrophy |
M62.5 |
AR; |
NA: NA |
Anaplastic mixed oligoastrocytoma |
NA |
FLT3; |
J00-J99: Diseases of the respiratory system |
Chronic obstructive pulmonary disease |
J40-J44, J47 |
ADORA2A; |
I00-I99: Diseases of the circulatory system |
Angiogenesis disorder |
I00-I99 |
KDR; |
H00-H59: Diseases of the eye and adnexa |
Choroidal neovascularisation |
H35 |
ESRRA; |
G00-G99: Diseases of the nervous system G00-G99 |
Pain |
G64, G90.0, R52, G89 |
ESR1; CDK1; IGF1R; AR; ADORA2A; ADK; |
C00-D49: Neoplasms |
Colon cancer |
C50 |
FLT3; |
C00-D49: Neoplasms |
Advanced solid tumor |
C00-C75, C7A, C7B |
MET; |
J00-J99: Diseases of the respiratory system |
Airway inflammation |
J00-J99 |
FLT3; |
K00-K95: Diseases of the digestive system |
Alcoholic hepatitis |
K70.1 |
AR; |
I00-I99: Diseases of the circulatory system |
Cerebrovascular ischaemia |
I61-I63 |
ADORA3; |
C00-D49: Neoplasms |
Prostate cancer |
C61 |
ESR1; AR; FLT3; |
J00-J99: Diseases of the respiratory system |
Allergic rhinitis |
J00, J30, J31.0, T78.4 |
ADORA2A; ESRRA; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Alopecia |
L65.9 |
AR; |
S00-T88: Injury, poisoning and certain other consequences of external causes |
Allergy |
T78.4 |
ADORA1; |
C00-D49: Neoplasms |
AML |
NA |
KDR; FLT3; |
C00-D49: Neoplasms |
Female androgenresponsive recurrent mammary cancer |
C50 |
AR; |
H00-H59: Diseases of the eye and adnexa |
Eye disorders |
H00-H59 |
ESR1; |
C00-D49: Neoplasms |
Fallopian tube cancer |
C57.0, D28.2 |
KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Hypertriglyceridemia |
E78.1, E78.2, E78.3, I47-I49 |
ADORA1; |
C00-D49: Neoplasms |
Renal cancer |
C64 |
KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Fibrosis |
L90.5 |
MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders |
Female sexual dysfunction |
F52 |
ESR1; |
N00-N99: Diseases of the genitourinary system |
Female infertility due to anovulation |
N97.0 |
ESR1; |
N00-N99: Diseases of the genitourinary system |
Female infertility |
N97.0 |
ESR1; |
C00-D49: Neoplasms |
Gastric cancer |
C16 |
KDR; |
C00-D49: Neoplasms |
Peritoneal cavity cancer |
NA |
KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Cystic fibrosis |
E84 |
AR; |
C00-D49: Neoplasms |
Hormone refractory prostate cancer |
C61 |
ESR1; AR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified |
Fatigue |
R53 |
ADORA1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified |
Convulsions |
R56.0 |
ADK; |
I00-I99: Diseases of the circulatory system |
High blood pressure |
I10-I16 |
CA2; |
I00-I99: Diseases of the circulatory system |
Heart disease |
I00-I52 |
MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders |
Schizophrenia |
F20 |
ESRRA; |
C00-D49: Neoplasms |
Colorectal cancer |
C18-C21 |
IGF1R; KDR; FLT3; |
C00-D49: Neoplasms |
Hematological malignancies |
C81-C86 |
AURKB; |
NA: NA |
Hematopoietic stem cell transplantation |
NA |
FLT3; |
NA: NA |
Hepatitis C virus infection |
NA |
ADORA3; |
C00-D49: Neoplasms |
Thyroid cancer |
C73 |
KDR; |
C00-D49: Neoplasms |
Advanced malignancies |
C00-C96 |
KDR; |
C00-D49: Neoplasms |
Advanced prostate cancer |
C61 |
ESR1; AR; |
I00-I99: Diseases of the circulatory system |
Hypertension |
I10-I16 |
ADORA1; ADORA2A; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Hyperlipidaemia |
E78 |
ESR1; ADORA1; |
NA: NA |
Postmenopausal disorder |
NA |
ESR1; |
N00-N99: Diseases of the genitourinary system |
Post-menopausal vaginal atrophy |
N95.2 |
ESR1; |
A00-B99: Certain infectious and parasitic diseases |
Human immunodeficiency virus infection |
B20-B26 |
FLT3; |
N00-N99: Diseases of the genitourinary system |
Prostate hyperplasia |
N40 |
AR; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Diabetic foot ulcer |
L88-L89 |
ADORA2A; |
Z00-Z99: Factors influencing health status and contact with health services |
Hormone replacement therapy |
Z79.890 |
ESR1; |
NA: NA |
Gonorrheal vaginitis |
NA |
ESR1; |
NA: NA |
GIST |
NA |
FLT3; |
H00-H59: Diseases of the eye and adnexa |
Glaucoma |
H40-H42 |
ADORA1; ADORA2A; ADORA3; |
C00-D49: Neoplasms |
Glioma |
C71 |
KDR; |
C00-D49: Neoplasms |
Gliosarcoma |
NA |
FLT3; |
C00-D49: Neoplasms |
Glioblastoma |
NA |
FLT3; |
G00-G99: Diseases of the nervous system G00-G99 |
Parkinson's disease |
G20 |
ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system |
Acute and chronic heart failure |
I50 |
ADORA1; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Acne vulgaris |
L70.0 |
ESR1; AR; ESRRA; |
K00-K95: Diseases of the digestive system |
Gastrointestinal disease |
K00-K93 |
ESRRA; |
C00-D49: Neoplasms |
Gastrointestinal cancers |
C15-C26 |
KDR; |
G00-G99: Diseases of the nervous system G00-G99 |
Multiple scierosis |
G35 |
ESR1; ADORA1; |
C00-D49: Neoplasms |
Multiple myeloma |
C90 |
IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 |
Motor neurone disease |
G12.2 |
IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Osteoporosis in post-menopausal women |
M80-M81 |
AR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Osteoporosis |
M80-M81, Z79.890 |
ESR1; AR; |
C00-D49: Neoplasms |
Ovarian cancer |
C56 |
KDR; |
C00-D49: Neoplasms |
Cutaneous Melanoma |
C43-C44 |
KDR; |
C00-D49: Neoplasms |
Head and neck cancer |
C07-C14, C32-C33 |
KDR; |
I00-I99: Diseases of the circulatory system |
Heart failure |
I50 |
AR; ADORA1; |
I00-I99: Diseases of the circulatory system |
Orthostatic hypotension |
I95.1 |
ADORA1; |
Z00-Z99: Factors influencing health status and contact with health services |
Oral contraceptive |
Z30 |
ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Arthralgia |
M25.5 |
ESR1; |
I00-I99: Diseases of the circulatory system |
Arteriosclerosis |
I70 |
ADORA2A; |
J00-J99: Diseases of the respiratory system |
Asthma |
J45 |
ADORA1; ADORA2A; ESRRA; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders |
Anxiety disorder |
F32, F40-F42 |
CYP3A4; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Diabetes |
E23.2, N25.1 |
ADORA1; FFAR1; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Dermatological disease |
L00-L99 |
AR; ESRRA; |
L00-L99: Diseases of the skin and subcutaneous tissue |
Dermatitis |
L20-L30 |
ESRRA; |
A00-B99: Certain infectious and parasitic diseases |
Sepsis |
A40, A41 |
ADORA1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified |
Growth failure |
R62.8 |
IGF1R; |
H00-H59: Diseases of the eye and adnexa |
Graves' ophthalmopathy |
H06.2 |
IGF1R; |
Z00-Z99: Factors influencing health status and contact with health services |
Contraception |
Z30 |
ESR1; AR; |
H00-H59: Diseases of the eye and adnexa |
Open-angle glaucoma |
H40-H42 |
CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Autoimmune diabetes |
E08-E13 |
ESR1; ADORA1; |
N00-N99: Diseases of the genitourinary system |
Atrophic vaginitis |
N95.2 |
ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Atrophy |
M62.571 |
ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Atrial fibrillation |
E78, I48 |
ADORA1; |
I00-I99: Diseases of the circulatory system |
Ischemia |
I99.8 |
ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 |
Epilepsy |
G40 |
ADK; |
G00-G99: Diseases of the nervous system G00-G99 |
Epileptic seizures |
G40, P90, R56 |
ADK; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Male hormonal deficiencies |
E20-E35 |
AR; |
NA: NA |
Male hypogonadism |
NA |
AR; |
A00-B99: Certain infectious and parasitic diseases |
Malaria |
B54 |
ADORA3; |
C00-D49: Neoplasms |
Malignant adrenal gland cancer |
C74.0 |
IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Non-insulin dependent diabetes |
E11.9 |
ESRRA; FFAR1; |
C00-D49: Neoplasms |
Non-small cell lung cancer |
C33-C34 |
MET; IGF1R; KDR; AXL; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Hormone deficiency |
E00-E90 |
ESR1; IGF1R; AR; |
C00-D49: Neoplasms |
Squamous cell cancer of head and neck |
NA |
KDR; |
G00-G99: Diseases of the nervous system G00-G99 |
Spinal muscular atrophy |
G00-G99 |
SMN1;SMN2; |
K00-K95: Diseases of the digestive system |
Chemotherapy-induced mucositis |
K12.3 |
MET; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Estrogen deficiency |
E28.39 |
ESR1; |
C00-D49: Neoplasms |
Melanoma |
C43 |
KDR; |
C00-D49: Neoplasms |
Medullary thyroid cancer |
C73 |
KDR; |
NA: NA |
Menopausal disorder |
NA |
ESR1; |
K00-K95: Diseases of the digestive system |
Duodenal ulcers |
K25-K27 |
CA2; |
G00-G99: Diseases of the nervous system G00-G99 |
Neuropathic pain |
G64, G90.0 |
ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system |
Neurological disease |
I21, I22, R52, R52.1-R52.2, R60.9, G89 |
ESR1; NPSR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Rheumatoid arthritis |
M05-M06 |
ESRRA; |
N00-N99: Diseases of the genitourinary system |
Dysmenorrhea |
N94.4-N94.6 |
ESR1; |
N00-N99: Diseases of the genitourinary system |
Dyspareunia |
N94.1 |
ESR1; |
C00-D49: Neoplasms |
Myeloid leukemia |
C92 |
FLT3; |
C00-D49: Neoplasms |
Metastatic castration-resistant prostate cancer |
C61 |
KDR; AR; |
C00-D49: Neoplasms |
Metastasis |
C00-C97 |
AXL; |
C00-D49: Neoplasms |
Metastatic breast cancer |
C50 |
KDR; |
N00-N99: Diseases of the genitourinary system |
Menopause symptoms |
N95.0 |
ESR1; |
N00-N99: Diseases of the genitourinary system |
Menorrhagia |
N92.0 |
ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue |
Arthritis |
M00-M25 |
ESRRA; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities |
Osteopetrosis |
Q78.2 |
ESR1; |
I00-I99: Diseases of the circulatory system |
Edema associated with congestive heart failure |
I50, R60.9 |
CA2; |
NA: NA |
Edema |
NA |
CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Endocrine disease |
E00-E35 |
AR; |
C00-D49: Neoplasms |
Solid tumours |
C00-D48 |
MET; AURKB; IGF1R; KDR; FLT3; CDA; |
C00-D49: Neoplasms |
Metastatic prostate cancer |
C61 |
AR; |
C00-D49: Neoplasms |
Metastatic HER2-negative gastric cancer |
NA |
MET; |
C00-D49: Neoplasms |
Metastatic colorectal cancer |
C18-C21 |
KDR; |
C00-D49: Neoplasms |
Pancreatic cancer |
C25 |
KDR; FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases |
Hypogonadism |
E23.0, E28.3, E29.1 |
ESR1; AR; |
C00-D49: Neoplasms |
Myelofibrosis |
C94.4, D47.4 |
FLT3; |
C00-D49: Neoplasms |
Myelodysplastic syndrome |
D46 |
KDR; |